Fungal pathogens are an important cause of death among patients with a suppressed immune system (eg. patients with cancer) and in premature infants. There are many challenges in dealing with invasive fungal infections, particularly those in the central nervous system (CNS). The most critical and essential step in improving treatment outcomes is the rapid diagnosis of these invasive fungal infections (IFIs). The glucan assay is an FDA-approved non-culture-based diagnostic system to detect IFIs that has been shown to be effective in adults. There is no study which systematically has investigated the effectiveness of glucan as a predictor of IFIs and as a monitor of therapeutic response in children. This is a multicenter retrospective study consisting of chart reviews of pediatric subjects ages 0-21 years with a diagnosis of probable or proven fungal meningo-encephalitis, admitted to the pediatric floors and pediatric or neonatal ICUs at Miller Children’s Hospital. The chart reviews will be conducted from July 2007 onward.
Characterization of (1->3)-Beta-D-Glucan as a Diagnostic Biomarker for Fungal Meningoencephalitis: a Multicenter Pediatric Case Series
063-12Principal Investigator: Conducted at:
Miller Children's & Women's Hospital Long BeachCurrently enrolling additional patients: